Prediction of outcome after diagnosis of metachronous contralateral breast cancer

[1]  M. Fernö,et al.  Abstract P4-09-07: Prediction of Outcome after Diagnosis of Metachronous Contralateral Breast Cancer , 2010 .

[2]  R. Arriagada,et al.  Relation of risk of contralateral breast cancer to the interval since the first primary tumour , 2009, British Journal of Cancer.

[3]  S. Duffy,et al.  Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival , 2009, British Journal of Cancer.

[4]  N Houssami,et al.  Early detection of second breast cancers improves prognosis in breast cancer survivors. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  M. Fernö,et al.  Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial. , 2009, European journal of cancer.

[6]  S. Duffy,et al.  Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias , 2009, Breast Cancer Research and Treatment.

[7]  J. Bonnema,et al.  Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis , 2009, Breast Cancer Research and Treatment.

[8]  King-Jen Chang,et al.  Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women , 2009, British Journal of Cancer.

[9]  M. Ringnér,et al.  Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs , 2008, BMC clinical pathology.

[10]  S. Duffy,et al.  Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. , 2008, American journal of epidemiology.

[11]  S. Duffy,et al.  Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? , 2008, British Journal of Cancer.

[12]  R. Pommier,et al.  Incidence and outcomes of contralateral breast cancers. , 2008, American journal of surgery.

[13]  E. Paci,et al.  Evaluation of service mammography screening impact in Italy. The contribution of hazard analysis. , 2008, European journal of cancer.

[14]  G. Vlastos,et al.  Survival after bilateral breast cancer: results from a population-based study , 2007, Breast Cancer Research and Treatment.

[15]  K. Czene,et al.  Incidence and prognosis of synchronous and metachronous bilateral breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Yu Shen,et al.  Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. , 2005, Journal of the National Cancer Institute.

[17]  S. Hilsenbeck,et al.  Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Czene,et al.  Genetic implications of bilateral breast cancer: a population based cohort study. , 2005, The Lancet. Oncology.

[19]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[20]  J. Kievit,et al.  Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  V. Kataja,et al.  Risk for distant recurrence of breast cancer detected by mammography screening or other methods. , 2004, JAMA.

[22]  Norman Wolmark,et al.  Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. , 2004, Journal of the National Cancer Institute.

[23]  E. Imyanitov,et al.  Molecular pathogenesis of bilateral breast cancer. , 2003, Cancer letters.

[24]  J Cuzick,et al.  Overview of the main outcomes in breast-cancer prevention trials , 2003, The Lancet.

[25]  E. Imyanitov,et al.  Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas , 2002, International journal of cancer.

[26]  D. Coyle,et al.  Surveillance mammography after treatment of primary breast cancer: a systematic review. , 2002, Breast.

[27]  R. Prescott,et al.  The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[28]  K. Hemminki,et al.  Morphological types of breast cancer in family members and multiple primary tumours: is morphology genetically determined? , 2002, Breast Cancer Research.

[29]  I. Olivotto,et al.  Diagnosis of Metachronous Contralateral Breast Cancer , 2001, The breast journal.

[30]  A. Verbeek,et al.  Routine follow-up examinations in breast cancer patients have minimal impact on life expectancy: a simulation study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  M. Gnant,et al.  Contralateral Breast Cancer: Molecular Differentiation Between Metastasis and Second Primary Cancer , 2001, Breast Cancer Research and Treatment.

[32]  D. Heron,et al.  Bilateral breast carcinoma , 2000, Cancer.

[33]  L. Dawson,et al.  Evolving perspectives in contralateral breast cancer. , 1998, European journal of cancer.

[34]  B Fisher,et al.  Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. , 1996, Journal of the National Cancer Institute.

[35]  B. Henderson,et al.  Clonal analysis of bilateral breast cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  S. Ciatto,et al.  Intensive Diagnostic Follow-up After Treatment of Primary Breast Cancer: A Randomized Trial , 1994 .

[37]  S. Ciatto,et al.  Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. , 1994, JAMA.

[38]  M. Indelli,et al.  Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. , 1994, JAMA.

[39]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[40]  L. Skoog,et al.  Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. , 1991, Journal of the National Cancer Institute.

[41]  L. Holmberg,et al.  Prognosis in bilateral breast cancer. Effects of time interval between first and second primary tumours. , 1988, British Journal of Cancer.

[42]  H. Adami,et al.  Age at first primary as a determinant of the incidence of bilateral breast cancer , 1986 .

[43]  H. Adami,et al.  Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population‐based case‐control study , 1985, Cancer.

[44]  A. Lees,et al.  Bilateral breast cancer in northern Alberta: risk factors and survival patterns. , 1984, Canadian Medical Association journal.

[45]  L. Bassett.  The value of surveillance mammography of the contralateral breast in patients with a history of breast cancer , 2010 .

[46]  Masato Takahashi,et al.  The impact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer , 2005, Breast cancer.

[47]  Earlybreastcancertrialistscol,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.